Ascend Wellness Holdings (AAWH) Total Non-Current Liabilities (2021 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Total Non-Current Liabilities came in at $27.6 million in Q1 2026, up 37.32% year-on-year from $20.1 million in Q1 2025, and up 24.62% quarter-over-quarter from $22.1 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Ascend Wellness Holdings' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $27.6 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 37.32% year-over-year to $27.6 million in Q1 2026; TTM through Mar 2026 was $27.6 million, a 37.32% increase from a year earlier, with the FY2025 full-year figure at $22.1 million, up 59.01% from the prior year.
- Total Non-Current Liabilities grew to $27.6 million in Q1 2026 per AAWH's latest filing, from $22.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $717.5 million in Q2 2023 and bottomed at $9.3 million in Q1 2024.
- The 5-year median for Total Non-Current Liabilities is $20.7 million (2025), against an average of $123.1 million.
- Across the five-year window, Total Non-Current Liabilities surged 523.93% in 2023 and plunged 98.69% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $115.0 million in 2022, then slumped by 91.73% to $9.5 million in 2023, then jumped by 46.3% to $13.9 million in 2024, then surged by 59.01% to $22.1 million in 2025, then climbed by 24.62% to $27.6 million in 2026.
- Per Business Quant, the three latest AAWH Total Non-Current Liabilities figures stand at $27.6 million (Q1 2026), $22.1 million (Q4 2025), and $26.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn | 27.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.59 Mn |
| Dec 31, 2025 | 22.14 Mn |
| Sep 30, 2025 | 26.42 Mn |
| Jun 30, 2025 | 21.27 Mn |
| Mar 31, 2025 | 20.09 Mn |
| Dec 31, 2024 | 13.92 Mn |
| Sep 30, 2024 | 13.42 Mn |
| Jun 30, 2024 | 11.85 Mn |
| Mar 31, 2024 | 9.28 Mn |
| Dec 31, 2023 | 9.52 Mn |
| Sep 30, 2023 | 9.52 Mn |
| Jun 30, 2023 | 717.54 Mn |
| Mar 31, 2023 | 705.56 Mn |
| Jun 30, 2022 | 115.00 Mn |
| Dec 31, 2021 | 126.40 Mn |